Tae-hyung Kim, Gounee Yang

Global Economic News

HANALL Biopharma and Daewoong Pharmaceutical will invest in a U.S. biomedicine firm to develop cell reprogramming, which is deemed as the next generation treatment modality.

The two companies announced Tuesday that they have signed an investment agreement with Turn Biotechnology based in Silicon Valley.

Through the investment, the two companies plan to expand their new drug development and innovations, and create synergy in R&D in ophthalmology, immunology, and anticancer treatment.

Turn Biotechnology researches and develops “cell reprogramming” technologies that can reverse cells’ biological clocks. It was established in 2018 by a team led by Dr. Vittorio Sebastiano of Stanford University School of Medicine. Currently, they are conducting preclinical research on aging-induced diseases in fields such as dermatology, immunology, and ophthalmology.

Turn Biotechnology’s patented platform technology, “ERA (Epigenetic Reprogramming of Age)” has a mechanism to turn back the clock on aging cells.